Multiple pathogens and prostate cancer

Table 4 Herpes simplex virus infections and prostate cancer

Study	Country	Method	Prostate cancer	Prostate non cancer controls	P value
Baker 1981 HSV 2 [70]	US	Immunofluorescent Tissues	34/50 68%	81/159 51%	0.001 s
Luleci 1981 HSV 2 [92]	Turkey	Serology	14/16 88%	22/35 63%	0.064 ns
Boldogh 1983 [93]	US	ISH	2/10 20%	1/22 5%	0.012 s
Haid 1984 HSV 2 [94]	US	Immunofluorescent tissues	7/27 26%	8/33 24%	0.668 ns
Leskinen 2003 HSV 1,2 [95]	Finland	PCR tissues	0/10	0/10
Korodi 2005 HSV 2 [96]	Finland	Serology	11/163 7%	20/288 7%	0.721 ns
Bergh 2007 HSV 1,2 [97]	Sweden	PCR tissues	0/201	0/201
Huang 2008 HSV 2 [87]	US whites US blacks	Serology Serology	70/765 9% 55/103 53%	89/915 10% 180/367 49%	0.729 ns 0.342 ns
Dennis 2009 HSV 2 [98]	US	Serology latent period tests 1 year 8 year	26/55 47% 20/56 36%	47/139 34% 35/156 22%	0.002 s 0.050 s
Hrbacek 2011 HSV 2 [88]	Czech	Serology	313/329 95%	99/105 94%	0.955 ns

ISSN: 1750-9378